A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Lung
Authors: Jesse Nussbaum, Azher Hussain, Anthony Ford, Peter Butera, Michael Kitt, Steve Smith, Aubrey Stoch, Marian Iwamoto
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Merck
OpenAlex ID: W4281817110
